Diagnosis of infection utilizing Accellix CD64

Sprung, Charles L.; Morales, Ricardo; Kasdan, Harvey L.; Reiter, A; Himmel, Y.; Meissonnier, Julien

doi:10.1016/j.jcrc.2015.04.078

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sprung et al. 82 have used similar technology to show that measurement of CD64 (Accellix-CD64), the neutrophil activation marker, correlates well with standard flow cytometry 82 and that it is able to differentiate infection from non-infectious inflammation in a timely manner. 83…”

Section: Moving Toward Point-of-care Testingmentioning

confidence: 99%

“…However, advances in point of care technology have meant that a rapid, automated cartridge-based flow cytometry device that is able to measure monocyte HLA-DR expression (Accellix-HLA-DR, LeukoDx, Jerusalem, Israel) within 25 min has now been developed. Sprung et al 82 have used similar technology to show that measurement of CD64 (Accellix-CD64), the neutrophil activation marker, correlates well with standard flow cytometry 82 and that it is able to differentiate infection from non-infectious inflammation in a timely manner. 83 Further development of this type of automated technology is likely to lead to improved immune biomarker assays, which could allow a stratified medicine approach to immunomodulation in sepsis.…”

Section: Moving Toward Point-of-care Testingmentioning

confidence: 99%

See 1 more Smart Citation

Immune therapy in sepsis: Are we ready to try again?

Davies

O’Dea

Gordon

2018

Journal of the Intensive Care Society

View full text Add to dashboard Cite

Immune therapy to ease the burden of sepsis has thus far failed to consistently improve patient outcomes. Advances in cancer immune therapy and awareness that prolonged immune-suppression in sepsis can leave patients vulnerable to secondary infection and death have driven resurgence in the field of sepsis immune-therapy investigation. As we develop and evaluate these novel therapies, we must learn from past experiences where single-mediator targeted immune therapies were blindly delivered to heterogeneous patient cohorts with complex and evolving immune responses. Advances in genomics, proteomics, metabolomics, and point-of-care technology, coupled with a better understanding of sepsis pathogenesis, have meant that personalised immune-therapy is on the horizon. Here, we review the complex immune pathogenesis in sepsis and the contemporary immune therapies that are being investigated to manipulate this response. An outline of the immune biomarkers that may be used to support this approach is also provided.

show abstract

Section: Moving Toward Point-of-care Testingmentioning

confidence: 99%